NVS 241220 95.00C (NVS241220C95000) Stock Options, News & Quotes

US OptionsDetailed Quotes

NVS241220C95000

Watchlist

3.80
-0.10-2.56%

15min DelayClose Dec 18 16:00 ET

3.80High3.80Low

Intraday

5D
Daily

News

Novartis AG (NOVN) Gets a Sell From Barclays
TipRanks05:45 ET · Ratings
The prospects of European Medical Care stocks are complex, with USA policies and new drug trial results being the key factors.
After falling from a high position in the last few months of 2024, European Medical Care stocks face the risks of US politics and the results of high-risk new drug trials in the new year.
Zhitong Finance01:48 ET
Top Gap Ups and Downs on Wednesday: CI, IBN, EA and More
Moomoo News18:00 ET · Markets
Express News | CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts
Benzinga14:45 ET
Express News | CDC Confirms First Severe Case Of H5N1 Bird Flu In U.S. On December 13; Patient Hospitalized With Severe Case Of Avian Influenza A Virus Infection In Louisiana
Benzinga11:08 ET
BioAge Stock Advances 14% On Novartis Research Collaboration
WSJDec 18 10:21 ET

Comments

Stock_Drift

1 hour ago

$BioAge Labs (BIOA.US)$ $Novartis AG (NVS.US)$

BioAge and Novartis seek drug targets for ageing-related diseases

10xStockPicks

Dec 15 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

10xStockPicks

Dec 14 21:19

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...

Asherboy88

Dec 11 08:09

$Novartis AG (NVS.US)$ what is happening ?? keeps going down